The somatostatin analog octreotide as well as peptide receptor-based radiotherapy, both of which primarily target SST2, have been used in the treatment of PTH-related protein (PTHrP)-dependent hypercalcemia caused by metastatic gastroenteropancreatic neuroendocrine tumors. This evidence concerns the gene PTHLH and neuroendocrine neoplasm.